- AbCellera Biologics is a little followed and largely uncovered company. What it is building however is known all throughout the biotech and pharma industries.
- With the likes of Bill Gates, Peter Thiel and DARPA as key backers, AbCellera is quietly creating a call option on vast swaths of new and emerging biotech.
- AbCellera, contrary to the competition, partners with its customers and locks in royalty agreements, leading to a very long but potentially vast revenue cycle.
- The sell-off in tech and high-growth names has punished AbCellera extremely hard and created a decent entry point. Investors cannot get past the current valuation and seem to lack the long-term vision to see the pot of gold at the end of the rainbow.
For further details see:
AbCellera Biologics: A Compounding Machine In Biotech Clothing